As low INPPB expression predicted poor outcomes in MM patients, we next evaluated whether manipulation of INPP4B expression could change sensitivity to chemotherapy reagent in the clinic, such as the first-line reagent widely applied in MM management, bortezomib. Here, INPP4B is linked to Miyoshi myopathy.